Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer.

Larsson P, Syed Khaja AS, Semenas J, Wang T, Sarwar M, Dizeyi N, Simoulis A, Hedblom A, Wai SN, Ødum N, Persson JL.

Int J Cancer. 2019 Aug 5. doi: 10.1002/ijc.32607. [Epub ahead of print]

PMID:
31381135
2.

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.

Tinzl M, Chen B, Chen SY, Semenas J, Abrahamsson PA, Dizeyi N.

PLoS One. 2018 Dec 18;13(12):e0209544. doi: 10.1371/journal.pone.0209544. eCollection 2018.

3.

The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.

Mandel A, Larsson P, Sarwar M, Semenas J, Syed Khaja AS, Persson JL.

Mol Med. 2018 Jun 27;24(1):34. doi: 10.1186/s10020-018-0035-4.

4.

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.

Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Gjörloff Wingren A, Mongan NP, Heery DM, Johnsson H, Abrahamsson PA, Dizeyi N, Luo J, Persson JL.

Oncotarget. 2016 Sep 27;7(39):63065-63081. doi: 10.18632/oncotarget.11757.

5.

Cyclin A1 and P450 Aromatase Promote Metastatic Homing and Growth of Stem-like Prostate Cancer Cells in the Bone Marrow.

Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, Allegrucci C, Persson JL.

Cancer Res. 2016 Apr 15;76(8):2453-64. doi: 10.1158/0008-5472.CAN-15-2340. Epub 2016 Feb 26.

6.

The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.

Semenas J, Hedblom A, Miftakhova RR, Sarwar M, Larsson R, Shcherbina L, Johansson ME, Härkönen P, Sterner O, Persson JL.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98. doi: 10.1073/pnas.1405801111. Epub 2014 Jul 28.

7.

Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer.

Tinzl M, Chen B, Chen SY, Semenas J, Abrahamsson PA, Dizeyi N.

PLoS One. 2013 Nov 8;8(11):e79573. doi: 10.1371/journal.pone.0079573. eCollection 2013. Erratum in: PLoS One. 2018 Dec 18;13(12):e0209544.

8.

Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.

Semenas J, Dizeyi N, Persson JL.

Drug Des Devel Ther. 2013 Aug 27;7:875-81. doi: 10.2147/DDDT.S45703. eCollection 2013. Review.

9.

Overcoming drug resistance and treating advanced prostate cancer.

Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL.

Curr Drug Targets. 2012 Sep 1;13(10):1308-23. Review.

Supplemental Content

Loading ...
Support Center